Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS Supplementary Table 4 ( Continued ) Characteristic, % Warfarin (n = 183,003 ) * Dabigatran (n = 86,293 ) * Rivaroxaban (n = 106,369 ) * Apixaban (n = 72,921 ) * Maximum Pairwise SMD after Weighting Emergency department visits in past 31-183 days (n) 0 83.6 83.9 83.8 83.9 0.01 1 12.7 12.6 12.6 12.5 0.01 ≥ 2 3.7 3.5 3.6 3.5 0.01 Medication use Corticosteroids 16.1 16.0 16.0 16.0 0.00 Thyroid replacement 19.4 19.2 19.3 19.3 0.00 Prescriber characteristics Age group, y < 40 19.0 19.0 19.0 19.1 0.00 40-59 61.1 61.2 61.2 61.1 0.01 ≥ 60 18.8 18.7 18.7 18.7 0.00 Unknown 1.1 1.1 1.1 1.0 0.01 Female 18.6 18.6 18.6 18.7 0.00 ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker; COPD = chronic obstructive pulmonary disease; NSAID = nonsteroidal antiinflammatory drug; SMD = standardized mean difference; SSRI = selective serotonin reuptake inhibitor. *Weighted cohort sample size is calculated by summing the stabilized inverse probability of treatment weights from each patient in the cohort. The size of this adjusted pseudo-population can differ slightly from the unadjusted count. y The CHA 2 DS 2 -VASc score assigns points for the presence of congestive heart failure, hypertension, age 65-74 years and age ≥ 75 years, diabetes melli- tus, stroke or transient ischemic attack, vascular disease, and female sex . 13 z The HAS-BLED score assigns points for the presence of hypertension, abnormal renal or liver function, stroke, bleeding history, labile international normalized ratio (INR), age ≥ 65 years, and antiplatelet drug or alcohol use . 14 Patients were not treated with warfarin, and INR testing was not per- formed, so labile INR was excluded from our scoring. x Days supply of use overlapped with the date of first prescription for dabigatran or rivaroxaban. Supplementary Table 5 Thromboembolic Stroke, Intracranial Hemorrhage, Major Extracranial Bleeding, Major Gastrointestinal (GI) Bleeding, and All-Cause Mortality Event Counts (Unweighted) During On-Treatment Follow-Up, By Anticoagulant Cohort Person-Years of On-Drug Follow-Up Thromboembolic Stroke Intracranial Hemorrhage Major Extracranial Bleed Major GI Bleed All-Cause Mortality Warfarin 68,785 814 605 1876 1488 2234 Dabigatran 30,368 279 104 839 737 677 Rivaroxaban 39,583 312 213 1335 1119 904 Apixaban 21,191 190 96 329 264 456 Total 159,927 1595 1018 4379 3608 4271 Supplementary Table 6 Adjusted Hazard Ratios (95% Confidence Intervals) for Pairwise Comparisons of Each NOAC vs Warfarin and Each NOAC vs Each Other NOAC for Thromboembolic Stroke, Intracranial Hemorrhage, Major Extracranial (Including Major Gastrointestinal) Bleeding, and All-Cause Mortality Thromboembolic Stroke Intracranial Hemorrhage Major Extracranial Bleed Major Gastrointestinal Bleed All-Cause Mortality NOAC vs warfarin Dabigatran vs warfarin 0.80 (0.70-0.93) 0.38 (0.31-0.47) 1.04 (0.96-1.14) 1.16 (1.06-1.27) 0.73 (0.67-0.80) Rivaroxban vs warfarin 0.72 (0.63-0.83) 0.65 (0.56-0.77) 1.38 (1.29-1.49) 1.48 (1.36-1.60) 0.81 (0.75-0.88) Apixaban vs warfarin 0.71 (0.60-0.83) 0.54 (0.43-0.68) 0.51 (0.45-0.58) 0.52 (0.45-0.60) 0.66 (0.60-0.74) NOAC vs NOAC Rivaroxaban vs dabigatran 0.90 (0.76-1.06) 1.71 (1.35-2.17) 1.32 (1.21-1.45) 1.27 (1.16-1.40) 1.12 (1.01-1.24) Rivaroxaban vs apixaban 1.02 (0.85-1.23) 1.21 (0.94-1.55) 2.70 (2.38-3.05) 2.83 (2.47-3.25) 1.23 (1.09-1.38) Dabigatran vs apixaban 1.14 (0.94-1.37) 0.70 (0.53-0.94) 2.04 (1.78-2.32) 2.23 (1.93-2.58) 1.10 (0.97-1.24) NOAC = nonvitamin K antagonist oral anticoagulant. 9.e5 The American Journal of Medicine, Vol 000, No 000, && 2019